(Q38008950)

26 August 2017

title

Translational medicine in hepatocellular carcinoma (English)

1 reference

26 August 2017

main subject

translational medicine

1 reference

Qiang Gao

1

1 reference

26 August 2017

Yinghong Shi

2

1 reference

26 August 2017

Xiaoying Wang

3

1 reference

26 August 2017

Jian Zhou

4

1 reference

26 August 2017

Shuangjian Qiu

5

1 reference

26 August 2017

Jia Fan

6

1 reference

26 August 2017

publication date

9 May 2012

1 reference

26 August 2017

published in

Frontiers of medicine

1 reference

26 August 2017

volume

6

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

122-133

1 reference

26 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Genetics of hepatocellular tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Molecular classification of hepatocellular carcinoma anno 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Oncomirs - microRNAs with a role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Identification of metastasis-related microRNAs in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

MicroRNA expression, survival, and response to interferon in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

miR-221 overexpression contributes to liver tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Aberrant DNA methylation profile of hepatocellular carcinoma and surgically resected margin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

New strategies in hepatocellular carcinoma: genomic prognostic markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Targeted therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Angiogenesis and anti-angiogenesis in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Prognostic significance of Beclin 1-dependent apoptotic activity in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Infiltrating memory/senescent T cell ratio predicts extrahepatic metastasis of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Thymostimulin in advanced hepatocellular carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Potential of immunotherapy for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

CD13 is a therapeutic target in human liver cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Significance of CD90+ cancer stem cells in human liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Liver stem cells and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Exome sequencing takes centre stage in cancer profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0193-7

Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial

21 January 2018

1 reference

12 December 2020

Immunotherapy of hepatocellular carcinoma

1 reference

12 December 2020

Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC

1 reference

12 December 2020

A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma

1 reference

12 December 2020

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

1 reference

12 December 2020

Recurrence of hepatocellular carcinoma

1 reference

12 December 2020

High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma

1 reference

12 December 2020

Molecular classification of hepatocellular carcinoma

1 reference

12 December 2020

Tumor stroma reaction-related gene signature predicts clinical outcome in human hepatocellular carcinoma

1 reference

12 December 2020

A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four -Fetoprotein Peptides

1 reference

12 December 2020

Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.

1 reference

12 December 2020

Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma

1 reference

12 December 2020

Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial

1 reference

12 December 2020

Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular Carcinoma

1 reference

12 December 2020

Mutation of p53 gene in regenerative nodules in cirrhotic liver

1 reference

12 December 2020

Phase II Randomized Trial of Autologous Formalin-Fixed Tumor Vaccine for Postsurgical Recurrence of Hepatocellular Carcinoma

1 reference

12 December 2020

A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma

1 reference

12 December 2020

High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma

1 reference

12 December 2020

Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection

1 reference

12 December 2020

Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma

1 reference

12 December 2020

A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer

1 reference

12 December 2020

10.1007/S11684-012-0193-7

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1004859617

0 references

1 reference